CAPLYTA is the only U.S. Food and Drug Administration (FDA) approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate.

Source: https://forextv.com/top-news/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update/

Doctors can rule out other causes of developmental delay and autism and then issue a formal diagnosis of FVS, which someone can only have if they have been exposed in-utero to sodium valproate.

Source: https://www.thejournal.ie/sodium-valproate-epilim-calls-redress-scheme-6015339-Mar2023/